High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1 2009 and improved with booster dosing in a randomized trial of HIV-infected adults

HIV Clinical Trials

Volumn 13, Issue 1, 2012, Pages 23-32

  Cooper, Curtis ^a   Klein, Marina ^b   Walmsley, Sharon ^c   Haase, David ^d   MacKinnon Cameron, Donna ^d   Marty, Kimberley ^e   Li, Yan ^f   Smith, Bruce ^d   Halperin, Scott ^d   Law, Barb ^g   Scheifele, David ^e  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^g PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

adjuvant; HIV; influenza; vaccine

Indexed keywords

INFLUENZA VACCINE; VIRUS RNA;

2009 H1N1 INFLUENZA; ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIVERTICULITIS; DRUG FATALITY; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEART INFARCTION; HEMAGGLUTINATION INHIBITION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SHIVERING; SIDE EFFECT; SKIN INDURATION; SUPRAVENTRICULAR TACHYCARDIA; SWEATING; SWELLING; THORAX PAIN; THROMBOSIS;

ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; PANDEMICS;

EID: 84863262308     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1301-23     Document Type: Article

References (54)

1. Beck JM, Rosen MJ, Peavy HH. Pulmonary complications of HIV infection. Report of the Fourth NHLBI Workshop. Am J Respir Crit Care Med. 2001;164:2120-2126. (Pubitemid 34020255)
2. Malaspina A, Moir S, Orsega SM, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis. 2005;191:1442-1450. (Pubitemid 40563355)
3. Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine. 2002;20(Suppl 5):B29-32. (Pubitemid 35435394)
4. Beck JM, Rosen MJ, Peavy HH. Pulmonary complications of HIV infection. 4th NHLBI Workshop. Vol. 164. Am J Respir Crit Care Med. 2001:2120-2126. (Pubitemid 34020255)
5. Fine AD, Bridges CB, De Guzman AM, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis. 2001;32:1784-1791. (Pubitemid 32532009)
6. Radwan HM, Cheeseman SH, Lai KK, Ellison IR. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis. 2000;31:604-606. (Pubitemid 32289599)
7. Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest. 1990;98:33-37. (Pubitemid 20223662)
8. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med. 2001;161:441-446. (Pubitemid 32116562)
9. Ragni MV, Ruben FL, Winkelstein A, Spero JA, Bontempo FA, Lewis JH. Antibody responses to immunization of patients with hemophilia with and without evidence of human immuno-deficiency virus (human T-lymphotropic virus type III) infection. J Lab Clin Med. 1987;109:545-549. (Pubitemid 17074019)
10. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med. 1987;316:673-676. (Pubitemid 17032953)
11. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine. 2000;18:3040-3049. (Pubitemid 30303809)
12. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med. 1995;182:1727-1737.
13. Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immu-nocompromised patients. Clin Infect Dis. 2009;48:1402-1412.
14. Klein MB, Lu Y, DelBalso L, Cote S, Boivin G. Influenzavi-rus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis. 2007;45:234-240. (Pubitemid 47041016)
15. Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis. 2011;52:122-127.
16. Crum-Cianflone NF, Eberly LE, Duplessis C, et al. Immuno-genicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis. 2011;52:138-146.
17. Ho J, Moir S, Wang W, et al. Enhancing effects of adju-vanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. AIDS. 2011;25:295-302.
18. Kajaste-Rudnitski A, Galli L, Nozza S, et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS. 2011;25:177-183.
19. Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011;52:248-256.
20. Orlando G, Pariani E, Mazza F, et al. Pandemic influenza vaccine in adult HIV-1-infected patients. AIDS. 2010;24:2142-2143.
21. Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One. 2011;6:e16496
22. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Micro-biol. 1999;37:937-943. (Pubitemid 29140593)
23. Committee for Proprietary Medicinal Products. Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. In: The European Agency for the E valuation of Medicinal Products-Human Medicines
24. Evaluation Unit, ed. Committee for Proprietary Medicinal Products/Biotechnology Working Party/214/96. London, UK: The European Agency for the Evaluation of Medicinal Products; 1997.
25. Cooper C, Thorne A, Klein M, et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One. 2011;6:e17758.
26. Powers DC, Smith GE, Anderson EL, et al. Influenza A virus vaccines containing purified recombinant H3 hemag-glutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis. 1995;171:1595-1599.
27. Skea DL, Barber BH. Adhesion-mediated enhancement of the adjuvant activity of alum. Vaccine. 1993;11:1018-1026. (Pubitemid 23303998)
28. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis. 2008;46:1310-1314. (Pubitemid 351589919)
29. Cooper CL, Davis H, Cameron DW. Influenza vaccination with 1/10th the full dose. N Engl J Med. 2004;351:2339-2340. (Pubitemid 39552754)
30. Cooper CL, Davis HL, Morris ML, et al. Safety and immu-nogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 2004;22:3136-3143. (Pubitemid 39043651)
31. Castellino F, Galli G, Del Giudice G, Rappuoli R. Generating memory with vaccination. Eur J Immunol. 2009;39:210-2105.
32. Baras B, Stittelaar KJ, Simon JH, et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One. 2008;3:e1401.
33. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adju-vanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet. 2007;370:580-589. (Pubitemid 47247854)
34. Banzhoff A, Nacci P, Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunoge-nicity meta-analysis. Gerontology. 2003;49:177-184. (Pubitemid 36438758)
35. Durando P, Fenoglio D, Boschini A, et al. Safety and immu-nogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immu-nodeficiency virus type 1-seropositive and-seronegative adults. Clin Vaccine Immunol. 2008;15:253-259. (Pubitemid 352025530)
36. Huang KL, Ruben FL, Rinaldo CR Jr, Kingsley L, Lyter DW, Ho M. Antibody responses after influenza and pneu-mococcal immunization in HIV-infected homosexual men. JAMA. 1987;257:2047-2050. (Pubitemid 17056745)
37. Tremblay CL, Rouleau D, Fortin C, et al. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine. 2011;29:1359-1363.
38. Fabbiani M, Di Giambenedetto S, Sali M, et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine. 2011;29:2836-2839.
39. Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1-42.
40. Nichol KL. Booster doses of influenza vaccine. JAMA. 1996;276:1857. (Pubitemid 26419162)
41. Iorio AM, Alatri A, Francisci D, et al. Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seroposi-tive and-seronegative ex-intravenous drug users. Vaccine. 1997;15:97-102. (Pubitemid 27060008)
42. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Mar-golick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA. 1989;262:779-783. (Pubitemid 19189001)
43. Anema A, Mills E, Montaner J, Brownstein JS, Cooper C. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med. 2008;9:57-61.
44. Cooper C, Thorne A, Walmsley S, et al. A controlled trial to compare the immunogenicity and efficacy of 3 seasonal influenza vaccine dosing strategies in HIV-infected adults. Presented at: Conference on Retro-viruses and Opportunistic Infections (CROI); 2010; San Francisco, CA.
45. Launay O, Desaint C, Durier C, et al. Safety and immu-nogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis. 2011;204:124-134.
46. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine. 2010;28:1740-1745.
47. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis. 2010;51:668-677.
48. Hancock K, Veguilla V, Lu X, et al. Cross-reactive a ntibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945-1952.
49. Skowronski DM, Hottes TS, Janjua NZ, et al. Prevalence of seroprotection against the pandemic (H1N1) virus after the 2009 pandemic. Can Med Assoc J. 2010;182:1851-1856.
50. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;361:2405-2413.
51. Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009;361:2414-2423.
52. Geretti AM, Brook G, Cameron C, et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med. 2008;9:795-848.
53. Statement on Seasonal Trivalent Inactivated Influenza Vaccine (TIV) for 2010-2011. Canada Communicable Disease Report. Volume 36; Advisory Committee Statement 6; August 2010. Ottawa: Public Health Agency of Canada; 2010.
54. Karlsson EA, Sheridan PA, Beck MA. Diet-induced obesity impairs the T cell memory response to influenza virus infection. J Immunol. 2010;184:3127-3133.